
SeaBeLife
Developing a range of medications to block regulated necrosis (or regulated cell death), from two families of patented molecules.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor investor investor | €0.0 | round | |
* | $1.5m | Grant | |
Total Funding | 000k |
EUR | 2020 |
---|---|
Revenues | 0000 |
EBITDA | 0000 |
Profit | 0000 |
EV | 0000 |
EV / revenue | 00.0x |
EV / EBITDA | 00.0x |
R&D budget | 0000 |
Source: Company filings or news article
Related Content
SeaBeLife is at the forefront of developing groundbreaking molecules aimed at inhibiting necroptosis, a form of programmed cell death implicated in severe medical conditions. The company focuses on creating medication candidates to address urgent medical needs in emergency medicine, particularly targeting acute liver failure (ALF) and acute kidney injury (AKI). By prioritizing the development of these innovative treatments, SeaBeLife aims to improve patient outcomes and save lives by preventing complications associated with these critical disorders. The business model revolves around the research and development of patented molecules, with the potential to generate revenue through successful clinical trials and partnerships with pharmaceutical companies. SeaBeLife serves healthcare providers and patients in the emergency medicine sector, addressing a significant gap in the market for effective treatments against necroptosis-related conditions. Keywords: necroptosis, emergency medicine, acute liver failure, acute kidney injury, molecules, programmed cell death, critical disorders, medication development, healthcare, patient outcomes.